Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2021-02-16 Major Shareholding Noti…
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2021-02-16 English
Major Shareholding Notification 2021
Major Shareholding Notification
2021-02-12 English
SCHEDULE 13G/A
Major Shareholding Notification
2021-02-12 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from KemPharm, Inc. addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a correspondence related to a regulatory filing process, specifically about the timing of a registration statement becoming effective. There is no financial data, report content, or detailed analysis present. The document is short (1880 characters) and serves as a formal request rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-02-12 English
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or fiscal period dates that would allow identification of a specific filing type. There is no indication of report titles, financial data, or announcements. Given the lack of discernible information, the document cannot be classified into any specific category and defaults to the fallback category for miscellaneous or unclassifiable filings.
2021-02-12 English
FORM 424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 424B3 prospectus supplement related to a securities offering, incorporating a Form 8-K current report filed with the SEC. The Form 8-K details the termination of a material definitive agreement, specifically a payoff letter terminating a credit agreement and repaying outstanding debt. The document includes legal and financial details about the payoff and termination of the credit facility, along with exhibits such as the payoff letter. This is a current report filing (Form 8-K) that provides an update on financing and capital structure changes, specifically the payoff and termination of a credit agreement. It is not a full financial report, earnings release, or annual report, but rather a regulatory filing reporting a material event related to capital/financing. Given the content focuses on financing activity and termination of debt, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a simple report publication notice, but a substantive filing about financing activity.
2021-02-09 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.